Fred Stephen Sarfo1, Bruce Ovbiagele2. 1. Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; Komfo Anokye Teaching Hospital, Kumasi, Ghana. Electronic address: stephensarfo78@gmail.com. 2. Department of Neurology, University of California, San Francisco, USA.
Abstract
BACKGROUND: Inadequate implementation of evidence-based preventive measures for individuals at high risk of cardiovascular disease (CVD) will only worsen the current epidemic of CVDs in sub-Saharan Africa. We assessed rates and predictors of statin utilization among two high CVD risk patient populations, people with type 2 diabetes mellitus (T2DM) and those with stroke, encountered across five hospitals in Ghana. METHODS: A cross-sectional study among 1427 patients with T2DM and 159 stroke survivors encountered at 5 hospitals (1 primary-level, 2 secondary level and 2 tertiary level) in Ghana between July 2015 and June 2018. We collected baseline demographic and clinical details including statin prescription from medical records. Factors associated with statin prescription among T2DM for primary prevention and stroke survivors for secondary prevention were evaluated using multivariate logistic regression analysis. RESULTS: Among patients with T2DM without CVDs, 240 (16.8%) were on statins for primary prevention. Factors associated with statin use among diabetics expressed as aOR (95% CI) were being treated at a tertiary level hospital 5.86 (3.22-10.68), hypertension comorbidity 1.80 (1.25-2.60), and lower income 0.43 (0.26-0.70). Among 159 stroke survivors, 22 (14.0%) were on statins with the following associated factors: lower income 0.16 (0.03-0.77), secondary level vs. tertiary level education 0.21 (0.05-0.97) and having T2DM 4.69 (1.63-13.49). CONCLUSION: Approximately 1 in 6 individuals with T2DM without CVD and 1 in 7 stroke survivors are prescribed statins in Ghana. Efforts to bridge this practice gap and improve access to life saving preventative medications for CVD risk reduction in low-and-middle income countries are urgently warranted.
BACKGROUND: Inadequate implementation of evidence-based preventive measures for individuals at high risk of cardiovascular disease (CVD) will only worsen the current epidemic of CVDs in sub-Saharan Africa. We assessed rates and predictors of statin utilization among two highCVD risk patient populations, people with type 2 diabetes mellitus (T2DM) and those with stroke, encountered across five hospitals in Ghana. METHODS: A cross-sectional study among 1427 patients with T2DM and 159 stroke survivors encountered at 5 hospitals (1 primary-level, 2 secondary level and 2 tertiary level) in Ghana between July 2015 and June 2018. We collected baseline demographic and clinical details including statin prescription from medical records. Factors associated with statin prescription among T2DM for primary prevention and stroke survivors for secondary prevention were evaluated using multivariate logistic regression analysis. RESULTS: Among patients with T2DM without CVDs, 240 (16.8%) were on statins for primary prevention. Factors associated with statin use among diabetics expressed as aOR (95% CI) were being treated at a tertiary level hospital 5.86 (3.22-10.68), hypertension comorbidity 1.80 (1.25-2.60), and lower income 0.43 (0.26-0.70). Among 159 stroke survivors, 22 (14.0%) were on statins with the following associated factors: lower income 0.16 (0.03-0.77), secondary level vs. tertiary level education 0.21 (0.05-0.97) and having T2DM 4.69 (1.63-13.49). CONCLUSION: Approximately 1 in 6 individuals with T2DM without CVD and 1 in 7 stroke survivors are prescribed statins in Ghana. Efforts to bridge this practice gap and improve access to life saving preventative medications for CVD risk reduction in low-and-middle income countries are urgently warranted.
Authors: Fred Stephen Sarfo; Manolo Agbenorku; Sheila Adamu; Vida Obese; Patrick Berchie; Bruce Ovbiagele Journal: J Neurol Sci Date: 2019-07-23 Impact factor: 3.181
Authors: Fred S Sarfo; John Akassi; Dominic Awuah; Sheila Adamu; Clara Nkyi; Mayowa Owolabi; Bruce Ovbiagele Journal: J Neurol Sci Date: 2015-08-04 Impact factor: 3.181
Authors: Michèle Ramsay; Mayowa O Owolabi; Onoja M Akpa; Felix Made; Akinlolu Ojo; Bruce Ovbiagele; Dwomoa Adu; Ayesha A Motala; Bongani M Mayosi; Sally N Adebamowo; Mark E Engel; Bamidele Tayo; Charles Rotimi; Babatunde Salako; Rufus Akinyemi; Mulugeta Gebregziabher; Fred Sarfo; Kolawole Wahab; Godfred Agongo; Marianne Alberts; Stuart A Ali; Gershim Asiki; Romuald P Boua; F Xavier Gómez-Olivé; Felistas Mashinya; Lisa Micklesfield; Shukri F Mohamed; Engelbert A Nonterah; Shane A Norris; Hermann Sorgho; Stephen Tollman; Rulan S Parekh; Chishala Chishala; Kenneth Ekoru; Salina P Waddy; Emmanuel Peprah; George A Mensah; Ken Wiley; Jennifer Troyer Journal: Hypertension Date: 2020-03-16 Impact factor: 10.190
Authors: Fred Stephen Sarfo; Dominic Otto Awuah; Clara Nkyi; John Akassi; Ohene K Opare-Sem; Bruce Ovbiagele Journal: J Neurol Sci Date: 2016-02-17 Impact factor: 3.181
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Jean Jacques Noubiap; Jean Joel Bigna; Jobert Richie Nansseu; Ulrich Flore Nyaga; Eric Vounsia Balti; Justin B Echouffo-Tcheugui; André Pascal Kengne Journal: Lancet Glob Health Date: 2018-09 Impact factor: 26.763